Michael H. Davidson to Hypolipidemic Agents
This is a "connection" page, showing publications Michael H. Davidson has written about Hypolipidemic Agents.
Connection Strength
11.569
-
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):905-914.
Score: 0.523
-
Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
Score: 0.478
-
Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):439-52.
Score: 0.450
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.406
-
Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011 Dec; 22(6):437-44.
Score: 0.388
-
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011 Mar-Apr; 5(2):76-81.
Score: 0.366
-
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
Score: 0.338
-
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. Cardiovasc Drugs Ther. 2009 Oct; 23(5):341-2.
Score: 0.334
-
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al. Cardiovasc Drugs Ther. 2009 Jun; 23(3):187-8.
Score: 0.326
-
Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Am J Cardiol. 2008 Apr 17; 101(8A):1B-2B.
Score: 0.302
-
Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
Score: 0.302
-
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
Score: 0.302
-
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008; 8(2):69-81.
Score: 0.296
-
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008; 28(10):615-23.
Score: 0.296
-
High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.
Score: 0.294
-
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
Score: 0.294
-
Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007; 10(4):215-21.
Score: 0.276
-
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
Score: 0.275
-
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
Score: 0.265
-
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
Score: 0.258
-
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
Score: 0.252
-
High-dose statins in acute coronary syndromes. JAMA. 2005 Jan 05; 293(1):38; author reply 38-9.
Score: 0.240
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
Score: 0.240
-
Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004 Sep-Oct; 47(2):73-104.
Score: 0.235
-
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol. 2004 Jul; 19(4):374-9.
Score: 0.232
-
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
Score: 0.219
-
Combination lipid-lowering therapy in diabetes. Curr Diab Rep. 2003 Jun; 3(3):263-8.
Score: 0.215
-
A look to the future: new treatment guidelines and a perspective on statins. Am J Med. 2002 Jun 03; 112 Suppl 8A:34S-41S.
Score: 0.201
-
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan; 11(1):125-41.
Score: 0.195
-
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. Am J Cardiol. 2001 Feb 16; 87(4A):1A-7A.
Score: 0.184
-
Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
Score: 0.182
-
Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
Score: 0.178
-
Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020 04; 31(2):108-110.
Score: 0.173
-
Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2000 Jan; 2(1):14-9.
Score: 0.170
-
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 1997 Sep 15; 80(6):797-8.
Score: 0.145
-
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
Score: 0.108
-
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct; 7(5):423-32.
Score: 0.108
-
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
Score: 0.098
-
Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
Score: 0.084
-
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
Score: 0.082
-
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
Score: 0.080
-
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008 Nov; 26(4):547-60.
Score: 0.078
-
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008 May 15; 101(10):1428-36.
Score: 0.076
-
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 01; 101(5):625-30.
Score: 0.074
-
Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007 May; 23(5):1121-30.
Score: 0.071
-
Safety of aggressive lipid management. J Am Coll Cardiol. 2007 May 01; 49(17):1753-62.
Score: 0.070
-
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
Score: 0.069
-
Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006 Nov; 12(15 Suppl):S405-11.
Score: 0.068
-
How low to target LDL? Nat Clin Pract Endocrinol Metab. 2006 Aug; 2(8):414-5.
Score: 0.067
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.064
-
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005 Jun; 27(6):715-27.
Score: 0.062
-
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab. 2004 May; 286(5):E718-24.
Score: 0.057
-
Biologic therapies for dyslipidemia. Curr Atheroscler Rep. 2004 Jan; 6(1):69-72.
Score: 0.056
-
Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002 Nov 20; 90(10B):50K-60K.
Score: 0.052
-
Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002; 19(3):169-78.
Score: 0.049
-
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001 Jul; 157(1):137-44.
Score: 0.047
-
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000 Aug 15; 86(4):406-11.
Score: 0.044
-
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000 Jul 15; 86(2):221-3.
Score: 0.044
-
ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
Score: 0.030
-
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 Jul 15; 167(1):225-31.
Score: 0.025
-
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
Score: 0.022
-
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
Score: 0.021
-
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008; 28(10):625-34.
Score: 0.018
-
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
Score: 0.013